1.	(a)	Antibody binds/eq/recognises only to cancer cells; because of antibody-antigen binding/eg; enzyme activates the drug;		
		at cancer cells only;	max 3	
	(b)	B lymphocytes produce antibodies/involved in humoral response; T lymphocytes involved in cell mediated immunity; Macrophages present antigens; (specific) B lymphocytes recognise/bind to antigen; increase in numbers by mitosis; produce plasma cells (which make antibodies); antibodies bind to and clump/ agglutinate virus; memory cells produced by 1 <sup>st</sup> exposure/cloned on 2 <sup>nd</sup> exposure; T lymphocytes(helpers) produce lymphokines/chemicals; which aid B lymphocyte cloning; encourages phagocytes to engulf clumped virus; killer T cells kill virus infected cells;	max. 6	
	(c)	Process of killing organisms might not be 100% efficient; live organisms might give rise to full-blown disease; attenuated organisms are non-virulent; but might mutate to virulent forms; immunity can decline - booster injections required; named side effects, eg allergies;		
		less effective due to changed antigens;	max. 3	[12]
2.	(a)	Formation of vesicle / phagocytosis; Derived from plasma membrane / eq;	2	
	(b)	(i) Lyosome;	1	
		<ul><li>(ii) Contain hydrolytic enzymes; To break down / digest bacterium;</li></ul>	2	[5]
3.	(a)	Weakened organism;	1	
	(b)	On further exposure to same microorganism; Antigen recognised; Faster response; Greater production of antibodies;	max 3	
	(c)	Number of reported cases falls after vaccination introduced; Because fewer individuals are vulnerable / less people to infect / more people immune;	2	

[7]

(d)	There was a reduction in number of new individuals being vaccinated / vaccine uptake was lower / higher number of babies;	1
(a)	A molecule which stimulates an immune response / antibody production / surface protein / glycoprotein / non-self protein;	1
(b)	(i) Plasma cells;	1
	(ii) Memory (B) cells;	1
(c)	Carried (an immunological) memory of the specific antigen; Produces large amounts of plasma cells quickly if the same antigen is encountered a second time; Rapid production of antibodies; <i>Not just 'bigger immune response'</i>	2 max
(d)		3 max

(d)

4.

Measles	Influenza
One antigen/	Several antigens/
unchanging	changing
One type of memory	Several types of
cell/ antibody	memory cell/
needed;	antibodies needed;

5. (a)

Х	;
$\checkmark$	;
$\checkmark$	;
X	;
	X ✓ ✓ X

4

2

- (b) (i) (Females vaccinated) before pregnancy / so baby not damaged / does not get Rubella; Reject immune / antibodies idea above
  - (ii) Males vaccinated **so not a source of infection** for unprotected **females**

[8]

6.	(a)	Protein / glycoprotein / molecule on surface of virus; Stimulates immune response / antibody production;	2	
	(b)	Greater / more rapid production of antibodies following second vaccination; First encounter takes time for B cells to become activated / clonal selection process / time delay before antibodies can be produced; Memory cells present as result of first vaccination;	3	[5]
7.	(a)	uses / breaks up / digests host nuclear / genetic material ( <i>allow references made to DNA /RNA instead of nuclear /genetic</i> ); virus DNA / genetic material inserted into hosts DNA / chromosome / genetic material; host cells amino acids are used to synthesize viral proteins; cell lysis; by enzyme (produced by expressing a virus gene); toxin production;	3 max	
	(b)	(shape of) virus fits / binds / attaches to receptors / proteins in the cell membrane (of host);	1	
	(c)	antigen / protein structure / shape changed by heat; (do not allow virus is killed/ destroyed or virus /antigen is denatured)	1	
	(d)	one type of antigen / protein / shape / one strain of virus; (allow virus does not mutate or virus does not change) same immune response generated;	2	[7]
8.	(a)	Bacterium (always found) in diseased organism and not in healthy organism; Bacterium (can be) cultivated / cultured / isolated; (Pure) cultures of the bacterium must cause the same disease / symptoms when introduced into (susceptible) other organisms; Can be re-isolated (from the other experimentally infected animals);	4	
	(b)	Spread by droplet infection / breathed in / airborne;	1	
	(c)	(i) Numbers falling <u>before vaccination</u> introduced;	1	

		(ii)	Better housing conditions / other social reason e.g. diet; Better awareness of disease / improved medical care; Fewer susceptible people / more immune; Availability of antibiotics post circa 1940; ( <i>reject before</i> ) <i>Reject 'hygiene'</i>	1 max	[7]
allow	<i>virus</i> same	<i>does n</i> immu	not mutate or virus does not change) ne response generated;	2	[7]
9.	(a)	(i)	A disease-causing organism / bacterium;	1	
		(ii)	Weakened organism;	1	
	(a)	(At 9 5% / popu Little	5% level) most people are immune; few vulnerable / susceptible individuals (remain in lation); Reject ' <i>not immune</i> ' e chance of <u>contact (</u> with affected person);	2 max	
	(c)	(i)	Number of <u>births</u> each year varies / changes seen more easily / allow valid comparisons to be made / provides an indication of likelihood of outbreak of disease;	1	
		(ii)	3600;	1	
	(d)	Antik No m Short <u>Antik</u> acros	bodies not produced by body; nemory cells; a-term / not lifelong; <u>bodies</u> ( <i>or context established</i> ) donated by mother / s placenta / in milk;	2 max	[8]
10.	(a)	(i) (ii)	Molecule/part of molecule/protein/glycoprotein; [ <i>Allow: polysaccharide</i> ] Stimulates immune response; These antigens/antibodies have complementary/particular shape;	2	
			[ <i>Reject: Active site</i> ] Allow fitting/binding with (relevant) antibody/antigen;	2	

PMT

(b) Calichaemicin delivered specifically to cancer cells/less likely to/will

		not h Lowe	arm normal/healthy cells; er dose of calichaemicin needed to be effective;	2	[6]
11.	(a)	mole that t	cule (on cell surface); triggers immune response;	2	
	(0)	(1)	2nd peak drawn higher; steeper gradient on second rise;	3	
		(ii)	because one dose does not give a high enough level of antibody to be effective/ because the antibody falls after a while;	1	
		(iii)	antigens are only single molecules/part of parasite; do not actually cause disease;	2	
	(c)	mala	ria sufferers would have parasites in red blood cells;	1	[9]
12.	(a)	add a wash add (	antibodies/enzyme; a to remove unbound antibodies; (colourless) solution; (mark correct responses sequentially)	3	
	(b)	antib other woul	odies specific/shape only fits one antigen; antigens different shape; d not bind to antibodies;	2 max	[5]
13.	(a)	(i) (ii)	<ul> <li>protein/immunoglobulin;</li> <li>specific to antigen;</li> <li>idea of "fit'/complementary <u>shape;</u></li> <li>1. virus contains antigen;</li> <li>2. virus engulfed by phagocyte/macrophage;</li> <li>3. presents antigen to B-cell;</li> <li>4. memory cells/B-cell becomes activated;</li> <li>5. (divides to) form clones;</li> <li>6. by mitosis;</li> <li>7. plasma cells produce antibodies;</li> </ul>	2 max	
			<ul> <li>antibodies specific to antigen;</li> <li>correct reference to T-cells/ cytokines;</li> </ul>	6 max	

PMT

PMT

	(b)	1. 2. 3. 4. 5. 6. 7.	antibody gene located using gene probe; cut using restriction enzyme; at specific base pairs; leaving sticky ends/unpaired bases; cut maize/DNA /vector using same restriction enzyme; join using DNA ligase; introduce vector into maize/crop/recombinant DNA into maize;	4 max	
	(c)	passiv perso memo	ve; n is not making own antibodies/antibodies not replaced; ory cells not produced;	2 max	
	(d)	fewer	ethical difficulties/less risk of infection;	1	[15]
14.	(a)	Stimu Secor Antiv	ulates memory cells; ndary response; renom / antibodies produced quicker;	max 2	
	(b)	Passiv No m Antiv	ve immunity; nemory cells produced; renom breaks down / destroyed;	max 2	
	(c)	Could	l transfer disease/Allergy/Immune response to antibodies from animal;	1	[5]
15.	(a)	47 21	3;	1	
	(b)	(i)	there is no difference in the proportion / number of influenza cases between the 5 vaccines; ( <i>reject vaccinated versus no vaccinated</i> )	1	
		(ii)	significant difference in proportion / number of cases of influenza between the vaccines / the null hypothesis should be rejected;	1	

	(c)	sample size small; possible differences in exposure to infection; exposure to different strains / mutants; possible differences in existing immunity; possible differences in sex / age; possible differences in socio-economic status;	2 max	[5]
16.	(a)	<ul><li>(i) Amino acids;</li><li>(ii) Peptide;</li></ul>	1 1	
	(b)	Contains specific sequence of amino acids; Complimentary shape enables attachment to antigen;	2	
	(c)	(Maternal antibodies) are antigens; Destroyed by (fetal) antibodies / lymphocytes;	2	
		Q Do not credit marks where source of antigens or antibodies/lymphocytes is ambiguous.		[6]